💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tenofovir Disoproxil Fumarate

CHEMBL1486 Phase 4 Onaylandı Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
635.5 g/mol
LogP
—
Phase
4

Tenofovir disoproxil fumarate (TDF) is the fumarate salt form of tenofovir disoproxil, an NRTI prodrug that forms the backbone of many HIV-1 antiretroviral regimens and is also approved for chronic hepatitis B treatment. See tenofovir-disoproxil for complete pharmacological details. It is also used for HIV pre-exposure prophylaxis (PrEP) and has been extensively studied in cardiovascular and chronic kidney disease contexts due to its renal effects.

Moleküler Ağırlık

635,5000 g/mol

TPSA

260,00 Ų

Terapötik Alanlar

Infectious Disease Rheumatoid Arthritis Osteoporosis Generalized Anxiety Disorder Insomnia Psoriasis Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Hyperlipidemia Obesity Lymphoma Hypertension Gout HIV/AIDS Hepatitis C Tuberculosis Heart Failure Cardiovascular Disease

Etki Mekanizması

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H34N5O14P

                    

                    
                    

                        
HBD / HBA

                        
3 / 18

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
19

                    

                    
                    
                    

                        
Ağır Atomlar

                        
43

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
Tenofovir disoproxil fumarate (TDF) is the fumarate salt form of tenofovir disoproxil, an NRTI prodrug that forms the backbone of many HIV-1 antiretroviral regimens and is also approved for chronic hepatitis B treatment. See tenofovir-disoproxil for complete pharmacological details. It is also used for HIV pre-exposure prophylaxis (PrEP) and has been extensively studied in cardiovascular and chronic kidney disease contexts due to its renal effects.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tenofovir Disoproxil Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1486.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6398764.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.